ANAPTYSBIO, INC - 10-Q Filing

AnaptysBio reports Q1 2026 financial results highlighting ongoing royalty monetization and collaboration milestones with GlaxoSmithKline.

SEC EDGAR ·

Tickers: $ANAB

Read the full article at SEC EDGAR

More Regulatory news